From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases

Effective treatment of inflammatory diseases is often challenging owing to their heterogeneous pathophysiology. Understanding of the underlying disease mechanisms is improving and it is now clear that eosinophils play a complex pathophysiological role in a broad range of type 2 inflammatory diseases...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Allergy (Copenhagen) 2022-03, Vol.77 (3), p.778-797
Hauptverfasser:	Pavord, Ian D., Bel, Elisabeth H., Bourdin, Arnaud, Chan, Robert, Han, Joseph K., Keene, Oliver N., Liu, Mark C., Martin, Neil, Papi, Alberto, Roufosse, Florence, Steinfeld, Jonathan, Wechsler, Michael E., Yancey, Steven W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized Asthma Cell activation Chronic obstructive pulmonary disease Churg-Strauss Syndrome - drug therapy clinical trials Corticosteroids Cytotoxicity eosinophilic diseases Eosinophils Granulomatosis Granulomatosis with Polyangiitis - drug therapy Humans Inflammatory diseases interleukin‐5 Leukocytes (eosinophilic) Life Sciences Lung diseases mepolizumab Monoclonal antibodies Obstructive lung disease Patients Phenotypes Polyposis Pulmonary Eosinophilia - drug therapy real‐world data Reducing agents Review Rhinosinusitis Treatment Outcome Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!